Shondra Miller shares her experience of starting a shared genome engineering resource at the St. Jude Children's Research Hospital. Learn more about her research projects and her views on the past, present, and future of the genome editing field in this podcast episode.
Dr. Bill Skarnes, Professor at The Jackson Laboratory, chats about how CRISPR edited stem cells are becoming a gold standard to study gene function and disease modeling.
Rebecca Shapiro, Assistant Professor at the University of Guelph, talks about CRISPR genome editing in fungal pathogens to understand their disease-causing mechanism. Her lab also works on gene drives in fungi for studying large scale genetic interactions and developing ways for treating fungal biofilms.
In this interview, Paul Dabrowski, CEO of Synthego, talks about how Synthego got started, his mantra behind leading the company, and future directions. He also offers insights into Synthego’s unique capabilities—the powerful combination of engineering and biology that enable scaling.
CRISPR has great potential in therapeutics, but CRISPR delivery in vivo remains a challenge. Researcher Dana Foss discusses her lab’s novel approach for specific delivery of CRISPR components in cells and tissues.
CRISPR is going beyond gene editing into a new area: diagnostics. Omar Abudayyeh and Jonathan Gootenberg, co-founders of SHERLOCK Biosciences, talk about the present advances and future of CRISPR diagnostics.
Kiana Aran, a biomedical engineering expert, talks about her research on CRISPR-Chip, a new biosensor that combines CRISPR & electronics to detect specific genes in genomic DNA.
Megan Hochstrasser, Science Communications Manager at the Innovative Genomics Institute, talks about the importance of CRISPR science communication and the ongoing efforts at IGI to help people understand this genome engineering tool.
Andre Watson, CEO of Ligandal, talks about how his company is improving the payload delivery of gene therapy, making it more accurate and efficient, to make new gene therapy a reality for the public.
Biotech and biopharma companies are in a phase of accelerated growth. Alex Philippidis, a science journalist at Genetic Engineering & Biotechnology News discusses the changing face of big pharma, biotech, and CRISPR gene editing industries, as they raise more money and the world changes around them.